A detailed history of Obermeyer Wood Investment Counsel, Lllp transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Obermeyer Wood Investment Counsel, Lllp holds 12,242 shares of PTGX stock, worth $582,964. This represents 0.02% of its overall portfolio holdings.

Number of Shares
12,242
Previous 12,242 -0.0%
Holding current value
$582,964
Previous $354,000 19.77%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

BUY
$21.79 - $32.15 $3,835 - $5,658
176 Added 1.46%
12,242 $354,000
Q4 2023

Jan 31, 2024

SELL
$14.05 - $23.44 $24,250 - $40,457
-1,726 Reduced 12.51%
12,066 $276,000
Q3 2023

Nov 08, 2023

BUY
$16.68 - $23.66 $19,682 - $27,918
1,180 Added 9.36%
13,792 $230,000
Q2 2023

Aug 04, 2023

SELL
$18.02 - $29.36 $19,389 - $31,591
-1,076 Reduced 7.86%
12,612 $348,000
Q1 2023

May 09, 2023

SELL
$10.78 - $25.38 $7,136 - $16,801
-662 Reduced 4.61%
13,688 $314,000
Q4 2022

Feb 08, 2023

SELL
$7.36 - $11.17 $7,050 - $10,700
-958 Reduced 6.26%
14,350 $156,000
Q3 2022

Dec 09, 2022

BUY
$7.86 - $11.71 $267 - $398
34 Added 0.22%
15,308 $129,000
Q2 2022

Aug 15, 2022

SELL
$7.06 - $25.52 $5.55 Million - $20.1 Million
-786,351 Reduced 98.09%
15,274 $121,000
Q1 2022

May 16, 2022

BUY
$23.34 - $36.08 $296,021 - $457,602
12,683 Added 1.61%
801,625 $19 Million
Q4 2021

Jan 31, 2022

BUY
$17.63 - $37.1 $216,020 - $454,586
12,253 Added 1.58%
788,942 $27 Million
Q3 2021

Oct 19, 2021

BUY
$12.95 - $49.69 $202,939 - $778,691
15,671 Added 2.06%
776,689 $13.8 Million
Q2 2021

Jul 29, 2021

BUY
$25.57 - $44.88 $9.59 Million - $16.8 Million
374,946 Added 97.12%
761,018 $34.2 Million
Q1 2021

May 10, 2021

BUY
$19.02 - $31.15 $7.34 Million - $12 Million
386,072 New
386,072 $10 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.34B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Obermeyer Wood Investment Counsel, Lllp Portfolio

Follow Obermeyer Wood Investment Counsel, Lllp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Obermeyer Wood Investment Counsel, Lllp, based on Form 13F filings with the SEC.

News

Stay updated on Obermeyer Wood Investment Counsel, Lllp with notifications on news.